SLAM
ALNY icon

Swiss Life Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Swiss Life Asset Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.83M Buy
29,327
+5,593
+24% +$1.69M 0.04% 346
2026
Q1 		$7.85M Buy
23,734
+1,262
+6% +$429K 0.04% 323
2025
Q4 		$8.94M Buy
22,472
+951
+4% +$421K 0.05% 287
2025
Q3 		$9.81M Sell
21,521
-2,268
-10% -$924K 0.05% 273
2025
Q2 		$7.76M Buy
23,789
+13,979
+142% +$3.87M 0.05% 282
2025
Q1 		$2.65M Sell
9,810
-3,004
-23% -$772K 0.02% 443
2024
Q4 		$3.01M Buy
12,814
+9,194
+254% +$2.42M 0.02% 404
2024
Q3 		$995K Buy
3,620
+1,671
+86% +$435K 0.01% 461
2024
Q2 		$474K Buy
+1,949
New +$308K 0.01% 498
2024
Q1 		– Sell
-3,410
Closed -$654K – 537
2023
Q4 		$654K Sell
3,410
-778
-19% -$133K 0.01% 529
2023
Q3 		$741K Sell
4,188
-129
-3% -$24.6K 0.01% 560
2023
Q2 		$821K Sell
4,317
-25
-0.6% -$4.96K 0.01% 540
2023
Q1 		$870K Buy
4,342
+345
+9% +$72.5K 0.01% 546
2022
Q4 		$953K Buy
3,997
+2,238
+127% +$477K 0.02% 495
2022
Q3 		$352K Sell
1,759
-108
-6% -$20.6K 0.01% 542
2022
Q2 		$273K Buy
+1,867
New +$265K ﹤0.01% 571

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Swiss Life Asset Management's ALNY Position: Q2 2026 in Review

Swiss Life Asset Management increased its Alnylam Pharmaceuticals (ALNY) stake by 24% in Q2 2026, buying an estimated $1.69M and bringing the position to 29,327 shares worth $8.83M. The position accounts for 0.04% of the portfolio, ranked #346.

Swiss Life Asset Management first reported a position in ALNY in Q2 2022 and has held it in 16 quarters since. The position peaked at $9.81M in Q3 2025. 490 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Swiss Life Asset Management held 29,327 shares of Alnylam Pharmaceuticals worth $8.83M as of Q2 2026.
  • Swiss Life Asset Management bought 5,593 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.69M.
  • Alnylam Pharmaceuticals made up 0.04% of Swiss Life Asset Management's portfolio in Q2 2026, its #346 holding.
  • Swiss Life Asset Management first reported a position in Alnylam Pharmaceuticals in Q2 2022 and has held it in 16 quarters since.
  • Swiss Life Asset Management's Alnylam Pharmaceuticals position peaked at $9.81M in Q3 2025.
  • 490 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Swiss Life Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.